IL27 and papilloma: In the K15-KRASG12D model, zibotentan can reverse IL27-driven changes in the pre-malignant niche and initiation of papillomas (Figure 6), suggesting that the contribution of ETAR signaling in epithelial cells is unlikely to explain the ETAR-dependent pro-tumor effects of IL27.